ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 156-164

  Mukherjee, Joydeep ^a   Ghosh, Anirban ^a   Ghosh, Asit ^b   Chaudhuri, Swapna ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Apoptosis; Brain tumors; ENU; Genetic instability; p53; RFLP; T11TS

Indexed keywords

ETHYLNITROSOUREA; GLYCOPROTEIN; GLYCOPROTEIN T11TS; IMMUNOMODULATING AGENT; MICROSATELLITE DNA; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA PROBE; EXON; EXPERIMENTAL MODEL; FEMALE; GENE MUTATION; GENOMIC INSTABILITY; GLIOMA; MALE; MICROSATELLITE INSTABILITY; NEWBORN; NICK END LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; RANDOM AMPLIFIED POLYMORPHIC DNA; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 33644637360     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2313     Document Type: Article

References (60)

1. Klein G, Klein E. Evolution of tumors and the impact of molecular oncology. Nature 1985; 315:190-5.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
3. Loeb LA. Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 1994; 54:5059-63.
4. Louis DN, Gusella JF. A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet 1995; 10:412-5.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
6. Dalrymple SJ, Jenkins RB. Molecular genetics of astrocytomas and meningiomas. Curr Opin Neurol 1994; 7:477-83.
7. Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP. Cytogenetic and molecular abnormalities in astrocytic gliomas. Oncol Rep 2000; 7:401-12.
8. von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 52:2987-90.
9. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993; 66:83-92.
10. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986; 6:4650-6.
11. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7:961-3.
12. Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors. Mol Carcinog 1995; 13:166-72.
13. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990; 18:4961.
14. Lantos PL. Chemical induction of tumors in nervous system. In: Thomas GT, ed. Neuro Oncology. New York, London: Curchill Livingstone, 1993:85-107.
15. Mukherjee J, Sarkar S, Ghosh A, Duttagupta AK, Chaudhuri S, Chaudhuri Swapna. Immunotherapeutic effects of T11TS/S-LFA3 against nitroso-compound mediated neural genotoxicity. Toxiol Lett 2004; 239-57.
16. Mukherjee J, Dutta S, Sarkar S, Begum Z, Ghosh A, Chaudhuri S, Chaudhuri Swapna. Preclinical changes in immunoreactivity and cellular architechture during thye progressive development of intracranial neoplasms and an immunotherapeutic schedule with a novel biological response modifier, the T11TS / S-LFA-3, Asian Pacific. J Cancer Prev 2002; 3:325-37.
17. Sarkar S, Begum Z, Dutta S, Chaudhuri S, Chaudhuri Swapna. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and antitumor activity against experimental brain tumor: A new approach to biological response modifier therapy. J Clin Expt Can Res 2002; 21:95-106.
18. Druckray H, Ivancovic S, Preussman R. Tetragenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature 1966; 210:1378-9.
19. Koestner A, Swenberg JA, Wechsler W. Transplacental production with ethylnitrosourea of neoplasms of the nervous system in Sprague-Dawley rats. A M J Pathol 1971; 63:37-39.
20. Lantos PL. The fine structure of periventricular pleomorphic gliomas induced transplacentally by N-ethyl-N-nitrosourea in BDIX rats with a note in their origin. J Neurological Sciences 1972; 17:443.
21. Wyllie AH, Morris RG. Hormone-induced cell death: Purification and properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am J Pathol 1982; 109:78-87.
22. Chattopadhyay P, Rathore A, Mathur M, Sarkar C, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumors. Oncogene 1997; 15:871-4.
23. Westphal M, Giese A, Meissner H, Zirkel D. Culture of cells from human tumors of the nervous system on an extracellular matrix derived from bovine corneal endothelial cells. In: Pollard JW, Walker JM, eds. Basic Cell Cuture Protocols. 2nd ed. Totowa, New Jersey: Humana Press, 2001:185-207.
24. Sambrook J, Fritsch EE, Maniatis T. Detection and analysis of proteins from cloned genes. Molecular Cloning a Laboratory Manual. 2nd ed. Cold Spring Hartor, NY: Cold spring Harbor Laboratory Press, 1989:47.
25. Cheah Y, Paigen B. Mapping new murine polymorphisms detected by random amplified polymorphic DNA (RAPD) PCR. Mamm Genome 1996; 7:549-50.
26. Peinado MA, Malkhosyan S, Velazquez A, Perucho M. Isolation and Characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 1992; 89:10065-9.
27. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558-61.
28. McClelland M, Welsh J. DNA fingerprinting by arbitrarily primed PCR. PCR Meth Appl 1994; 4:S59-65.
29. Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H, Yoshimura K, Terada M, Perucho M, Yoshida T. The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. Gastroenterology 2003;125:1330-40.
30. Werely CJ, Heyns CF, Van Velden DJ, Van Helden PD. DNA fingerprint detection of somatic mutations in benign prostatic hyperplasia and prostatic adenocarcinoma. Genes Chromosomes Cancer 1996; 17:31-6.
31. Toth-Fejel S, Muller P, Ham B, Esvelt K, Dumas N, Calhoun K, Pommier R. DNA fingerprints provide a patient-specific breast cancer marker. Ann Surg Oncol 2004; 11:560-7.
32. Singh KP, Roy D. Somatic mutations in stilbene estrogen-induced Syrian hamster kidney tumors identified by DNA fingerprinting. J Carcinog 2004; 3:4.
33. Marczinek K, Hampe J, Uhlmann K, Thiel G, Barth I, Mrowka R, Vogel S, Nurnberg P. Genomic difference analysis by two-dimensional DNA fingerprinting reveals typical changes in human low-grade gliomas. Glia 1998; 23:130-8.
34. Joshi AR, Sinha S, Dil-Afroz, Sulaiman IM, Banerji AK, Hasnain SE. Alterations in brain tumor DNA detected by a fingerprinting probe. Indian J Biochem Biophys 1996; 33:455-7.
35. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, Zhang Y, Wang Y, Wen H. p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10:2775-8.
36. Liu WH, Kaur M, Makrigiorgos GM. Detection of hotspot mutations and polymorphisms using an enhanced PCR-RFLP approach. Hum Mutat 2003; 21:535-41.
37. Aka K, Bruner JM, Bondy ML, Ligon K, Nishi T, del Giglio A, Moser RP, Levin VA, Saya H. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J Neurooncol 1993; 16:125-33.
38. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocytes apoptosis by Propidium iodide staining and flowcytometry. J Immunol Methods 1991; 139:271-9.
39. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Feature of apoptotic cells measured by flowcytometry. Cytometry 1992; 13:795-808.
40. Piqueras B, Autran B, Derbe P, Gorochov G. Detection of apoptosis at the single cell level by direct incorporation of fluorescein-dUTP in DNA strand breaks. BioTechniques 1996; 20:634-40.
41. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119:493-501.
42. Thein SL, Jeffreys AJ, Gooi HC, Cotter F, Flint J, O'Connor NT, Weatherall DJ, Wainscoat JS. Detection of somatic changes in human cancer DNA by DNA fingerprint analysis. Br J Cancer 1987; 55:353-6.
43. Jeffreys AJ, Wilson V, Thein SL. Hypervariable 'minisatellite' regions in human DNA. Nature 1985; 314:67-73.
44. Armour JA, Patel I, Thein SL, Fey MF, Jeffreys AJ. Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics 1989; 4:328-34.
45. Armour JA, Jeffreys AJ. Recent advances in minisatellite biology. FEBS Lett 1992; 307:113-5.
46. Jin S, Mazzacurati L, Zhu X, Tong T, Song Y, Shujuan S, Petrik KL, Rajasekaran B, Wu M, Zhan Q. Gadd45a contributes to p53 stabilization in response to DNA damage. Oncogene 2003; 22:8536-40.
47. Girlando S, Slomp P, Caffo O, Amichetti M, Togni R, Dvornik G, Tomio L, Galligioni E, Dalla Palma P, Barbareschi M. p21 expression in colorectal carcinomas: A study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. Virchows Arch 1999; 435:559-65.
48. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
49. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17:1364-74.
50. Baccouche S, Daoud J, Frikha M, Mokdad-Gargouri R, Gargouri A, Jlidi R. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. Ann NY Acad Sci 2003; 1010:752-63.
51. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993; 14:1085-9.
52. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. 2003; 198:69-75.
53. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004; 210:197-203.
54. Mukherjee J, Ghosh A, Sarkar S, Mazumdar M, Sarkar P, Duttagupta AK, Chaudhuri S. T11TS/S-LFA3 induces apoptosis of the brain tumor cells: A new approach to characterise the apoptosis associated genetic changes by arbitrarily primed -PCR. Cancer Lett 2004; 222:23-8.
55. Mukherjee J, Ghosh A, Sarkar P, Mazumdar M, Banerjee C, Chaudhuri Swapna. Immunotherapy with T11TS/SLFA3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status. Anticancer Res 2005; 25:2905-20.
56. Russell JH, Ley TJ. Lymphocyte mediated cytotoxicity. Ann Rev Immunol 2002; 20:323-70.
57. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 2001; 165:2075-81.
58. Spiro I, Rice GC, Durand RE, Stickler R, Ling CC. Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiol Oncol Biol Phys 1984; 10:1275-80.
59. Yao KS, Clayton M, O'Dwyer PJ. Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst 1995; 87:117-22.
60. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379:88-91.